Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells
Yuki TenjinKazuyoshi NakamuraShiho IshizukaKoichi SaruwatariRyo SatoYusuke TomitaSho SaekiHidenori IchiyasuKazuhiko FujiiTakaaki ItoTakuro Sakagami
Author information
JOURNAL OPEN ACCESS

2019 Volume 58 Issue 22 Pages 3261-3265

Details
Abstract

Small cell lung cancer (SCLC) transformation of epidermal growth factor receptor (EGFR) mutant adenocarcinoma (ADC) during EGFR tyrosine kinase inhibitor (TKI) treatment is an example of a rare subset of acquired drug resistance. We herein report the case of a 75-year-old man treated with afatinib who was then diagnosed with SCLC transformation. After two years of successful treatment with afatinib, the tumor relapsed, and a re-biopsy revealed SCLC harboring EGFR exon 19 deletion. We encountered a case of transcriptional alteration, potentially important for SCLC transformation of EGFR mutant lung ADC, that was recognized via the expression of NOTCH, ASCL1 and RB1 on immunohistochemical staining.

Related papers from these authors
© 2019 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top